Stocks

Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?

Investors focused on the Medical space have likely heard of Moderna (MRNA), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of MRNA and the rest of the Medical group's stocks.

Moderna is one of 1122 individual stocks in the Medical sector. Collectively, these companies sit at #11 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. MRNA is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for MRNA's full-year earnings has moved 13.77% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Based on the most recent data, MRNA has returned 220.51% so far this year. Meanwhile, the Medical sector has returned an average of -7.87% on a year-to-date basis. This shows that Moderna is outperforming its peers so far this year.

To break things down more, MRNA belongs to the Medical - Biomedical and Genetics industry, a group that includes 511 individual companies and currently sits at #175 in the Zacks Industry Rank. On average, this group has lost an average of 11.27% so far this year, meaning that MRNA is performing better in terms of year-to-date returns.

Investors in the Medical sector will want to keep a close eye on MRNA as it attempts to continue its solid performance.


Zacks' Top Picks to Cash in on Artificial Intelligence

In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.

See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>

Click to get this free report

Moderna, Inc. (MRNA): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Investing

Latest Stocks Videos

JPMorgan Says Buy the Dip as Investors Face Volatility

Dec 02, 2021

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More